Identification of hyper-rewired genomic stress non-oncogene addiction genes across 15 cancer types

Jessica Xin Hjaltelin1, Jose M. G. Izarzugaza2, Lars Juhl Jensen1, Francesco Russo1, David Westergaard1 and Søren Brunak1,3

Non-oncogene addiction (NOA) genes are essential for supporting the stress-burdened phenotype of tumours and thus vital for their survival. Although NOA genes are acknowledged to be potential drug targets, there has been no large-scale attempt to identify and characterise them as a group across cancer types. Here we provide the first method for the identification of conditional NOA genes and their rewired neighbours using a systems approach. Using copy number data and expression profiles from The Cancer Genome Atlas (TCGA) we performed comparative analyses between high and low genomic stress tumours for 15 cancer types. We identified 101 condition-specific differential coexpression modules, mapped to a high-confidence human interactome, comprising 133 candidate NOA rewiring hub genes. We observe that most modules lose coexpression in the high-stress state and that activated stress modules and hubs take part in homoeostasis maintenance processes such as chromosome segregation, oxireductase activity, mitotic checkpoint (PLK1 signalling), DNA replication initiation and synaptic signalling. We furthermore show that candidate NOA rewiring hubs are unique for each cancer type, but that their respective rewired neighbour genes largely are shared across cancer types.

Tumours can be affected by both intrinsic and extrinsic stresses, such as genomic, proteotoxic, metabolic, hypoxic stress etc. In this study, we focus on genomic stress. Many solid tumours present widespread aneuploidy or DNA damage, and these extreme manifestations of genomic instability constitute a stress phenotype. Recent findings demonstrate that patients with high-mutation-burden tumours have improved survival. Genomic instability can in turn instigate other stress forms such as mitotic and proteotoxic stresses. Although some NOA genes have been studied extensively, they have not been identified or analysed from a systems perspective or characterised as a group that may be sub divided further.

Differential coexpression has recently been employed as a supplement to traditional differential gene expression. This method identifies changes of coexpression between two states, hence focusing more on the dynamics, or the ‘rewiring’ of the network interactions, as opposed to simply quantitative measures of gene expression.

We present the first systems level analysis for NOA gene and module discovery, where we have investigated 15 cancer types. We used copy number alteration (CNA) data and gene expression profiles from The Cancer Genome Atlas (TCGA) to identify significant differential coexpression modules between high and low genomic stressed tumours. We furthermore applied physical protein interactome information to identify NOA rewiring hub genes. We identified 101 candidate NOA modules and 133 candidate NOA rewiring hub genes. We highlighted four activated NOA modules and used these as examples to demonstrate the unique rewiring roles of NOA genes in the human protein interactome. We found that even though the NOA rewiring hub genes are mainly cancer-specific, they regulate highly similar neighbour genes across cancer types.

INTRODUCTION

Non-oncogene addiction (NOA) is the phenomenon where tumour cells present stress phenotypes that instigate a dependency on support genes for survival. This phenomenon was first characterised in Solimini et al. More specifically, NOA genes have been defined as non-mutated genes that are upregulated to uphold the stress phenotypes of cancer cells, making them stress-specific. Tumour cells are under various types of stresses and possess fewer regulatory mechanisms to compensate for perturbations (i.e. buffering capacity) compared with their normal counterparts. The activation of NOA genes is unnecessary for normal cells but essential for cancer cells that are burdened by the stress caused by for example oncogenes. A new generation of treatments are starting to exploit these Achilles’ heels, owing to experimental and clinical evidence showing that they have a much wider space that can be mined for drug targets compared with the classical oncogenes.

Tumours can be affected by both intrinsic and extrinsic stresses, such as genomic, proteotoxic, metabolic, hypoxic stress etc. In this study, we focus on genomic stress. Many solid tumours present widespread aneuploidy or DNA damage, and these extreme manifestations of genomic instability constitute a stress phenotype. Recent findings demonstrate that patients with high-mutation-burden tumours have improved survival. Genomic instability can in turn instigate other stress forms such as mitotic and proteotoxic stresses. Although some NOA genes have been studied extensively, they have not been identified or analysed from a systems perspective or characterised as a group that may be subdivided further.

Differential coexpression has recently been employed as a supplement to traditional differential gene expression. This method identifies changes of coexpression between two states, hence focusing more on the dynamics, or the ‘rewiring’ of the network interactions, as opposed to simply quantitative measures of gene expression.

RESULTS

Defining the genomic instability stress phenotype

Aneuploidy and copy number alterations are known hallmarks of cancer and their frequency vary largely between tumours even within the same cancer type. Genome instability can be a side effect of oncogenic perturbations and result in an enormous stress burden for the tumour. To estimate tumour groups of high and low degree of genomic instability, we used as a proxy the CNA burden, which is the fraction of the autosomal genome that is affected by copy number alterations (both gains and losses). We calculated the CNA burden for each of the 11,034 CNA profiles...
available from TCGA, based on which we derived a CNA burden distribution for 33 cancer types. From the distribution, tumours were grouped into low and high-stress categories based on the first quartile and the median, respectively (Fig. 1a). We specifically applied this approach, leaving out samples with medium-level CNA burden, to perform differential analyses on the low- and high-end CNA cases. We thus define high-stress phenotype tumours as those with more than 19.2% genome-wide copy number variation and low-stress phenotypes as those with <7.0% genome-wide CNA.
Fig. 1 Defining stress phenotypes. a Genome-wide % CNA burden distribution quartiles for defining stress groups. The CNA burden distribution for all TCGA cancer types (n = 33) with CNA profiles (n = 11,034) was used to define the stress phenotype groups indicated by the dashed lines at 7.0% (low stress) and 19.2% (high stress). The pie charts represent the distribution of cancer types within the selected samples that are used for analysis (n = 5367) covering the 15 cancer types. Some of the cancer types are altered to match the RNA-Seq data set such as KIPAN (to Kidney-Clear and Kidney-Papillary) and STES (to Stomach). The grey cancer names are those used in this paper (for full names see Supplementary Table S1). b CNA burden distributions for tumour samples applied in the analyses. Of the 33 cancer types, 24 cancer types have both RNA-Seq and CNA samples, which is needed for our analyses. Furthermore, cancer types with at least 20 samples in both high and low-stress groups were included in the comparative analyses. This resulted in including 15 cancer types (black) and excluding 9 (grey). The cancer types left have in concert 3356 stress and 1601 non-stress phenotype samples. Onwards, we will refer to ‘Brain’ as LGG, since only this brain cancer type is used for further analyses.

To perform differential gene and coexpression analysis between high and low stress, we selected TCGA patients with both CNA and gene expression profiles available. In addition, cancer types with fewer than 20 samples in any of the stress groups were excluded from the comparative analysis. Analyses were thus performed on the remaining 15 TCGA cancer types comprising overall 3356 high-stress and 1601 low-stress phenotype samples, respectively (Fig. 1b). A schematic of the computational method is shown in Supplementary Fig. S1.

Widespread loss of coexpression during genomic stress

We performed a differential gene expression analysis for the two stress conditions for all cancer types and examined the upregulated genes for NOA stress-relief processes (Log2 fold change ≥1.5 and FDR < 0.05) (Supplementary Fig. S2). A Gene Ontology (GO) enrichment analysis showed that these genes are involved in cell differentiation, multicellular development and neurogenesis amongst several cancer types. Differential gene expression analysis can complement a network-based differential coexpression analysis, and we therefore integrated the differential gene expression profiles into the subsequent analyses as additional information.

Differential coexpression analysis can be used to understand condition-specific activation of functional modules based on the idea of guilt-by-association.\textsuperscript{14,15} We carried out differential coexpression analysis using DiffcoEx\textsuperscript{14} for each of the 15 cancer types separately to identify modules that are activated by genomic stress (see Methods section for details). This method is an extended version of the Weighted Gene Co-expression Network Analysis (WGCNA) tool.\textsuperscript{14} Instead of calculating coexpression modules given one condition, DiffcoEx calculates the differential coexpression modules for two given conditions; in this case high and low genomic stress. The approach can thus minimise generic cancer interactions, such as proliferation-related modules, which can be non-specific for the condition in question.\textsuperscript{16}

We used this strategy to identify differential coexpression modules for all cancer types. Genomic CNA levels can correlate with coexpression changes, which can give rise to results linked to altered stoichiometry and not the stress response itself. To avoid this, we performed differential coexpression analyses only for genes uncorrelated for copy number and gene expression (see Methods for details). No significant modules were found for prostate cancer, which is unsurprising, since it is one of the cancer types with lowest mutation burden profile\textsuperscript{17} (Fig. 1b). A total of 125 differential coexpression modules were identified across the 14 cancer types ranging in size from 75 to 3125 genes with a median of 315 genes (Supplementary Fig. S3). We found that 100 of the 125 differential coexpression modules lose coexpression in the high stress compared with the low-stress condition. Cervical and skin cancers have the highest numbers of differential coexpression modules, 21 and 15, respectively, whereas liver cancer represents the minimum with four modules. To acquire more knowledge on the functional properties of these modules, we investigated both the differential gene expression and physical protein–protein interactions within the modules (Fig. 2). Here we observe that even though cervical cancer has the most differential modules, these were comprised of few differentially expressed genes and physical interactions.

To assess the robustness to subsampling, we performed a fivefold cross validation test where each cancer type was subsampled using 90 and 70% of the data. For the 90% cross validation analysis, we obtained gene set overlaps ranging from 61 to 94% and for the 70% cross validation gene set overlaps from 59 to 93% (Supplementary Fig. S4).

Single-gene differential expression can detect upregulated NOA genes within modules. Despite the massive loss of coexpression in the high-stress state, single genes within the module can rewire and participate in other functional modules. The human protein interactome has, for example, been shown to be dominated by many weak stoichiometric interactions and thus be highly dynamic.\textsuperscript{19} Moreover, since many proteins exert their function in protein complexes, physical protein–protein interaction modules can be useful to deduce functional knowledge on novel modules. Hence, we mapped the stress-specific differential coexpression modules to an annotated and high-quality human interactome InWeb_InBioMap (InWeb_IM)\textsuperscript{19} obtaining 101 condition-specific differential coexpression modules with physical protein–protein interactions (with a minimum module size of five) (Supplementary Table S2). The modules range in size from 5 to 1651 proteins.

Single-gene rewiring in differentially activated stress modules

It can be considered that stress-relieving NOA genes behave as multifunctional hub genes capable of rewiring and participating in several functionalities when dealing with fluctuating stress levels.\textsuperscript{20} Therefore, we are especially interested in genes that are differentially upregulated themselves while having several deregulated physically interacting neighbours. These were the most promising candidates for regulators that shift functionality when experiencing stress. We defined the degree of rewiring as the number of genes that (1) undergo significant differential gene expression and (2) physically interact with the NOA rewiring hub gene. We defined rewiring genes as genes that were significantly upregulated (FDR < 0.05, Log2FC ≥0.5) and have a degree of rewiring of at least three. We defined the latter threshold because our stringent definitions of NOA rewiring interactions leads to a very sparse network. In addition, three is the minimal number of interactions for a hub protein to configure a functional sub-module.\textsuperscript{21,22} We thus ended up obtaining 133 NOA rewiring hub genes in total (Supplementary Table S3). To compare these genes to previous findings, we searched the literature for each gene and found associations to the NOA mechanism for 26% of them (Supplementary Table S4). These are enriched for functions such as chromosome maintenance, oxioreductase activity, mitotic checkpoint, DNA replication initiation and synaptic signalling. Surprisingly, 19% of the genes take part in synaptic signalling, which may be due to brain cancer being the cancer type with most NOA rewiring hubs. However, only two genes overlap between the 25 synaptic genes and 44 brain cancer rewiring hubs.
High stress differential coexpression modules across 14 cancer types. Differential coexpression modules were obtained for high stress vs. low-stress samples using differential coexpression analysis for 15 cancer types. No modules were found for prostate. The differential coexpression modules were mapped to a physical human protein interactome. In addition, differential gene expression was performed on the same stress groups. The brown and turquoise fractions illustrate significant differentially up or down expressed genes, respectively. Darker areas are genes that participate in a physical protein–protein interaction. Grey areas are genes that are not differentially expressed. Numbers within each bar are the number of genes per module. DE: differential expression; PPI: protein–protein interaction.
The four modules with highest fraction of upregulated genes in their physically interacting subsets are Brain-M1, Kidney-Papillary-M1, Lung-Adeno-M1 and Uterus-M1 (Fig. 3a–d). From these, we extracted the NOA rewiring hub genes and their first-order interacting neighbours to functionally examine. These were functionally annotated using the gene enrichment tool gProfileR revealing that they take part in mitotic checkpoint, DNA repair and chromatin segregation regulation processes. We also found regulation of ubiquitin-ligase activity, Ephrin receptor activation and oxireductase activity. Ephrin and Ephrin receptors have been linked to tumorigenesis, but bidirectional roles and divergent expression patterns have been observed across tumours.24 This could imply a stress-buffering role, since their multifunctional characteristics benefit from the fluctuating stress environments that tumours experience.

Some rewiring hubs are found in stress modules across several cancer types. For example, we observe that PLK1, CCNB1/2, CCNA2,
AURKB and BUB1B are shared across 6–9 cancer types (Fig. 3e) and physically interact with several deregulated neighbouring genes in our activated modules (Fig. 3a–c). PLK1, AURKB and BUB1B are mitotic kinases and regulatory genes during mitotic cell cycle and especially PLK1 and AURKB have been studied as promising NOA drug targets.\(^2,\(^5\) PLK1 is a multifunctional protein during cell cycle following DNA damage\(^2\) regulating both mitotic entry/exit, DNA damage checkpoint, spindle formation, etc. BUB1B is involved in the spindle assembly checkpoint and ensures proper chromosome segregation. Recent studies highlight that BUB1B dependency is especially elevated in brain cancer.\(^27,\(^28\) This is supported by our analysis showing that BUB1B is the most upregulated NOA rewiring hub in brain cancer.

Overlapping stress-activated genes across cancer types

Genes found in more than one cancer type may be generically activated genes essential for stress response and can function as targets for broader therapeutics that are not specific for a certain cancer type. To acquire an overview of genes participating in more than one tumour, we counted the number of times a gene was found in the differential modules across cancer types. To estimate the expression activity for each gene, we used their median LogFC across cancer types (Supplementary Table S5). Since NOA genes are often upregulated to uphold a robust cancer state, we looked into the functionality of genes with high differential expression (Log2FC ≥ 0.5) that are also shared across more than six cancer types. These are mainly involved in cell cycle regulation, spindle and chromosome stabilisation, cell adhesion junction, transmembrane signalling, metabolism or synaptic processes (Fig. 4).

Interestingly, several of these genes (BUB1B, CDC25C, CENPE, kinesin and CCNB1) are involved in the PLK1 signalling pathway, which is a regulator of several DNA damage control and genotoxic instability processes. We found that the hub genes (BUB1B, CDC25C, CENPE, kinesin and CCNB1) make up an essential response across many cancer types. More studies are needed to validate this as a novel NOA pathway. We also identified a group of upregulated synaptogenic genes involved in vesicular trafficking (LIN7A, SYT1 and SNAP25). This is consistent with mounting evidence showing that cancer cells depend on intercellular communication via the release of extracellular vesicles for viability purposes. Extracellular vesicles have been shown to contain oncoproteins and RNAs and are proposed to have a mechanism of transport as neurocytological transport.\(^29\)

NOA rewiring hubs regulate similar neighbours across cancer types

Next, we investigated the amount of overlap of the NOA rewiring hubs across cancer types to establish whether the stress response is cancer type-specific. For this analysis we used the Jaccard index as a measure of overlap between lists of hubs for each cancer type pair (Fig. 5a).

Brain, stomach, lung-squamous and uterus cancer are the cancer types with most rewiring hubs and neighbours. The cancer types kidney, lung, breast and brain cancer have the highest overlap of NOA rewiring hubs. However, most of the cancer types have low hub overlap with an average Jaccard index of 0.07 (the average of all gene set comparisons within a cancer type). The most shared rewiring hubs are BUB1B (brain, lung-adeno, kidney-clear, kidney-papillary and stomach cancer), CYP11A1 (bladder, brain, kidney-clear and uterus cancer) and CCNB1 (brain, kidney-papillary, lung-adeno and lung-squamous cancer). BUB1B is involved in the mitotic checkpoint and is in normal tissue enriched in testis. Recent studies have shown that it interacts with known NOA genes, PLK1 and APC/C, to induce delay of anaphase due to spindle defects.\(^30,\(^31\) CYP11A1, mostly abundant in testis and adrenal gland, is involved in drug biotransformation and could be an indicator of cancer therapy responses. Finally, the cyclin CCNB1 involved in cell cycle regulation is expressed in all tissues. We searched the human pathology atlas\(^32\) to verify if the upregulation of these genes are negatively correlated with survival. Indeed, both upregulation of BUB1B and CCNB1 were found to be a marker for unfavourable prognosis across several cancer types (Supplementary Fig. S5).

For this analysis we used the Jaccard index to calculate the overlap of the NOA rewiring hubs. However, most of the cancer types have low hub overlap with an average Jaccard index of 0.07 (the average of all gene set comparisons within a cancer type). The most shared rewiring hubs are BUB1B (brain, lung-adeno, kidney-clear, kidney-papillary and stomach cancer), CYP11A1 (bladder, brain, kidney-clear and uterus cancer) and CCNB1 (brain, kidney-papillary, lung-adeno and lung-squamous cancer). BUB1B is involved in the mitotic checkpoint and is in normal tissue enriched in testis. Recent studies have shown that it interacts with known NOA genes, PLK1 and APC/C, to induce delay of anaphase due to spindle defects.\(^30,\(^31\) CYP11A1, mostly abundant in testis and adrenal gland, is involved in drug biotransformation and could be an indicator of cancer therapy responses. Finally, the cyclin CCNB1 involved in cell cycle regulation is expressed in all tissues. We searched the human pathology atlas\(^32\) to verify if the upregulation of these genes are negatively correlated with survival. Indeed, both upregulation of BUB1B and CCNB1 were found to be a marker for unfavourable prognosis across several cancer types (Supplementary Fig. S5).

Validation using external datasets

To validate our stress modules, we obtained two breast cancer datasets from METABRIC (Molecular Taxonomy of Breast Cancer International Consortium),\(^33\) which included samples with both gene expression data and CNA profiles. The two datasets comprised of \(N_1 = 997\) (METABRIC discovery data set) and \(N_1 = 995\) patients (METABRIC validation data set). For data set 1 we obtained 336 high-stress phenotype samples and 319 low-stress phenotype samples. For data set 2 we obtained 300 high-stress phenotype samples and 375 low-stress phenotype samples.

Although the breast cancer data set was not the optimal cancer type for validation, due to the limited results (four modules), we did obtain a significant overlap of stress module genes between the TCGA set and both the METABRIC datasets (Supplementary Fig. S7). We furthermore validated two (AURKB and CCNB1) of the five NOA rewiring hub genes.
rewire to obtain a new state of homeostasis. A tumour state seems to be largely robust despite a disrupted generic buffering mechanism against stresses can be suggested since most tumours have highly diverse mutation profiles, but more similar expression profiles. In this study, we present the first systems-based method to understand NOA genes and pathways conditioned upon the intrinsic stress: genomic instability. We focused on genomic stresses, including DNA damage stress, proteotoxic stress and mitotic stress, but the approach can be extended to other types of stresses as well. We used the publicly available TCGA tumour profiles (CNA and RNA-Seq data) for 15 cancer types and grouped samples into high and low genomics stress based on their CNA burden.

Most studies have focused on gene-centric mutation-driven NOA genes (synthetic lethality), where perturbation of a specific gene, e.g. an oncogene, promotes the dependency on a NOA gene. An example is PARP1 inhibitors used to treat BRCA2-deficient tumours. Since BRCA2 tumours have a deficiency in the DNA repair pathway, they are even more dependent on PARP1 for DNA repair. A separate type of NOA genes is independent of any oncogenic mutation; these genes are instead activated when the cell is burdened by a generic cellular stress. An example is HSF1, a transcription factor that controls heat-shock proteins and is activated upon proteotoxic stress. HSF1 deficiency in mice and in cancer cells lowers tumourigenesis. HSF1 provides essential stress relief through proteasome-mediated protein degradation pathways by induction of heat-shock proteins, such as HSP90, which is overexpressed in many cancers.

We performed comparative analyses obtaining differential coexpression modules for the high-stress groups for each of the 15 cancer types. Most of the modules were negatively coexpressed compared with the low-stress group, suggesting that these rewire into other modules with processes more needed for the new burdened tumour state. We mapped the modules to physical interactions and gene-specific differential gene expression values and identified 101 modules and 133 rewiring hubs related to genomic instability. We found that the rewiring hubs are mainly enriched for processes involved in chromosome maintenance, oxireductase activity, mitotic checkpoint, DNA replication initiation and synaptic signalling. Moreover, 19% of the rewiring hubs are involved in synaptic signalling, which can be related to the fact that brain tissue has a higher level of gene expression compared with other tissue. However, recent evidence corroborates that (1) cancer cells can repurpose neuronal communication mechanisms to fuel tumourigenesis and (2) that there is no association between high mutation burden and improved survival in brain cancer, unlike other cancer types.

In contrast to classical oncogenic targets, which are essential for tumour transformation events, our NOA rewiring hubs and modules are involved in maintenance functions for homeostasis purposes; some of which are comparable to the effects of tumour suppressor genes. We found that despite the small overlap of hub rewiring genes across tumour types, the overlap of their respective neighbours is much larger. This suggests that stress-activated mechanisms are shared across cancer types.

Thus, increasing efforts are being directed towards mapping out cancer dependencies for example by systematically performing genome-wide vulnerability screens on large numbers of cancer cell lines or by using advanced computational algorithms. Limitations arise when working with collected tumour data that are not optimised for tumour stress analysis. For example, TCGA
samples can be highly heterogeneous and co-vary with tumour stage, other stresses, treatment effects, gene expression etc. To measure tumour stress environments, more tailored technologies and strategies are more fitting. For example, single-cell technology has the potential to measure varying levels and types of stresses across subpopulations of cells. Other examples are synthetic dosage lethality, in which gene dosage is taken into account, or conditional synthetic lethality that takes into account the tumour microenvironment. Another limitation is that the NOA hubs need further experimental and clinical tests to validate their causal effects as drug targets.

Few experimentally validated NOA genes exist that have been associated with related stresses, let alone entire databases. Based on a manual literature search, we found that the 26% of the NOA rewiring hubs have been associated to the NOA mechanism. Some of the NOA rewiring hubs, such as AURKB, CHEK1/2 and HSPA1B, are already being considered and tested as promising cancer therapeutics. The general mechanisms behind these are either to exploit a ploidy-burdened phenotype by inducing ploidy overload (AURKB, PLK1, tubulins, CHEK1/2) or to reduce levels of stress-relief proteins (HSPA1B). Aurora kinases, such as AURKB, are undergoing phase III clinical trials in various cancer types due to their multifunctionality and promising effects when treated in combination with, e.g. chemotherapy. Cancer types due to their multifunctionality and promising effects when treated in combination with, e.g. chemotherapy.

Our findings identify 101 genomic stress-activated NOA modules comprising of 133 NOA rewiring hub genes across 14 cancer types. Our method shows that activated NOA modules are enriched for homoeostasis maintenance functions, such as PLK1 signalling, DNA repair and spindle and chromosome maintenance. Finally, we observe the tendency that NOA rewiring hub genes share many neighbours across cancer types suggesting a generic stress response. We suggest that these shared neighbour genes could be important candidates for use in combinatorial therapy together with cancer-specific oncogenes as a step towards cancer precision medicine. The approach provides the first comprehensive view of condition-specific NOA genes and can pave the way to better understanding of the NOA concept in future studies. We believe that the next era of cancer therapeutics will exploit intrinsic and extrinsic conditional vulnerability mapping to leverage how tumour stresses can be utilised for drug targeting.

**METHODS**

**Data**

Copy number alteration (CNA) data (n = 11,034) were obtained from The Cancer Genome Atlas (TCGA) (https://cancergenome.nih.gov/) on 7 April 2017. TCGA RNA-Seq data (raw read counts) were obtained from the GEO (Gene Expression Omnibus) (https://www.ncbi.nlm.nih.gov/geo/) data set GSE62944 as input to the pre-processing and differential gene expression analysis in DESeq2. From the literature we manually curated a list of experimentally validated non-oncogene addiction genes using full article texts (Supplementary Table S4).

**Data pre-processing**

Genes with zero variance and a low raw count (<10 in more than 90% of the samples) were excluded from the analysis as recommended by the WGCNA pipeline authors for pre-processing of RNA-Seq data (https://labs.genetics.ucla.edu), as they tend to reflect noise. This also ensures that genes not expressed in a certain cell type are left out of the comparative analysis. DESeq2 (version 1.10.1) was used to perform pre-processing on the raw RNA-Seq counts. The DESeq2 function varianceStabilizingTransformation is a global normalization approach performed to minimise variation caused by technical errors. Unwanted variation in the data, such as age and sex, were corrected for using the svaseq function implemented in the SVA R package (version 3.18.0). Age and sex information on the TCGA samples are available at firebrowse (http://firebrowse.org). We furthermore corrected the breast cancer samples for PAM50 subtypes using svaseq.

Genes with a significant RNA-Seq copy number correlation were removed from the analysis to avoid confounding effects due to stoichiometric alterations. This was done from pre-calculated TCGA correlation tables available at firebrowse (version 2016_01_28). The correlation coefficients were calculated based on the Log CNA and RNA-Seq expression for each corresponding feature using Pearson correlation. "Correlations between copy number and RNA-Seq expression," (http://firebrowse.org/). We used genes that did not show significantly RNaseq-CNA correlation, thus genes with a Benjamini and Hochberg-corrected q-value > 0.05.

Defining low and high-stress groups Pre-processed TCGA mutation and copy number segment tables were used to group tumour samples into stress and non-stress phenotypes. Copy number segment tables were used to calculate the percentage-wise base pairs affected by CNA for each tumour.

\[
\text{CNV burden} = \frac{\sum n_{\text{gain}} + n_{\text{loss}}}{n_{\text{autosomal}}}
\]

(1)

To calculate the percentage-wise CNA burden, segments of CNA gains and losses were determined, and their total genomic length (in number of base pairs: \(n_{\text{gain}}\) and \(n_{\text{loss}}\)) was summed and calculated as a percentage of the size of the autosomal genome \(n_{\text{autosomal}}\). The autosomal genome length was calculated from NCBi’s Build 36 (hg18) from UCSC (https://genome.ucsc.edu/), since this is the reference used for the TCGA CNA SNP-array data. We excluded CNAs with a segment mean in the range –0.2 < segment mean < 0.2 to provide a threshold for when to infer gain and loss of CNAs. Segment mean is the Log2 ratios of the tumour copy number to the normal copy number.

All TCGA tumour samples (n = 11,034) were considered when defining the thresholds for low and high mutation burden samples. Our definition of the low-stress phenotype includes those samples presenting a CNA burden equal or lower than the upper boundary of the first quartile. Similarly, the high-stress phenotype was defined as those presenting a CNA burden above the lower limit of the medium quartile. Only low and high mutation burden samples were used for further stratification. The exact thresholds for the low and high group are 7.0% and 19.2% CNA burden, respectively.

Differential gene expression analysis using edgeR Raw counts were used as input to edgeR to perform differential gene expression analysis. The data were normalised using the edgeR functions calcNormFactors and afterwards, dispersion estimates were done using the functions estimateGLMCommonDisp and estimateGLMTagwiseDisp. In the model, we corrected for covariates age and sex. Finally, we used glmFit to perform the differential analysis between stresses and obtained results with FDR < 0.05 to acquire significantly differentially expressed genes in the high-stress state. Genes were analysed for enriched GO Biological Processes using gprofiler in R.

Differential coexpression modules using DiffCoEx Differential coexpression analysis was performed for the high versus low CNA burden groups using the R implementation of DiffCoEx. DiffCoEx uses the WGCNA statistical framework to identify differential coexpression modules. We implemented the topological overlap measurement (from the WGCNA framework) when identifying coexpression modules, which takes into account the interconnectedness of the network when performing correlation analysis. The approach can be useful to exclude spurious or isolated connections during network construction and is more robust than pairwise correlation alone for clustering genes by similarity. The differential coexpression measurements are transformed into dissimilarity scores between genes, and then hierarchical clustering is used to detect gene modules. The hierarchical clustering was applied using the dynamic tree cut method. The soft threshold \(\beta\) is a parameter used to scale the correlation networks such that the weights of larger correlation differences are emphasised in comparison with lower ones. These were calculated for each of the 15 cancer types using the function pickSoftThreshold from the WGCNA package. A minimum module size of 30 was used to exclude small modules in the results. Besides the mentioned settings, default parameters from WGCNA were used for the clustering.

To access the significance of the differential coexpression modules, we performed a permutation procedure (included in the DiffCoEx package)
using dispersion statistics. For each DiffCoEx run, samples were permuted $n = 1000$ times between the two stress conditions to generate a null distribution from which we could evaluate the significance of the modules. A dispersion value was calculated for each module, which is a measure of the correlation change for a group of genes. The $p$-value was calculated based on the number of times a permutation yielded a higher dispersion than the dispersion value of our module. The permutation was done using a function from DiffCoEx using the R framework.\textsuperscript{15}

Physical differential coexpression modules and rewiring hubs

The differential coexpression modules were then mapped to the scored physical human interactome, InWeb.IM.\textsuperscript{19} These modules were selected if they have a minimum of five genes. Genes were assigned as a NOA rewiring hub if they are significantly upregulated (FDR < 0.05, Log$_2$FC $\geq 0.5$) and have at least three physically interacting genes that are significantly differentially regulated (FDR < 0.05).

Functional analysis

The differential coexpression modules mapped to physical protein–protein interactions from InWeb.IM were annotated in Cytoscape. Due to the large sizes of these modules, we furthermore used the MCL clustering algorithm to obtain smaller submodules for functional analysis. To gain functional knowledge for these submodules, we used gProfilerR (version r1732_e89_eg36)\textsuperscript{13} to perform gene enrichment analysis on Gene Ontology (GO) Biological Processes (BP) terms. GO BP terms with highest significant FDR-corrected $p$-values (FDR < 0.05) were used.

Protein interaction data

InWeb.IM is a scored and benchmarked protein–protein interaction (PPI) database, including interactions from humans and model organisms (human orthologs) collected from various resources.\textsuperscript{19} The InWeb.IM score is based on metrics such as reproducibility of the interaction data. The collection (version 2016.02.05) consists of 504,608 unique interactions covering 17,104 proteins. Only high-confident InWeb.IM interactions with scores higher than the author-recommended cutoff of 0.156 were used in covering 17,104 proteins. Only high-confidence (version 2016_02_05) consists of 504,608 unique interactions.

Cross validation and significance testing

We performed a fivefold cross validation for each cancer type to assess the robustness of our results. We randomly subsampled each of the sample groups (of high and low stress) and repeated this five times for each cancer type. We performed both a 90 and 70% subsampling. We then calculated the significance of the gene overlap compared with the original results using the Fisher’s exact test for the hypergeometric distribution implemented in the R function phyper. We tested the significance of NOA shared neighbour overlaps by performing a within-degree node label permutation. This approach generated permuted networks that kept their degree distribution but randomly re-assigned the nodes. We built 1000 random networks and for each of these, we calculated the neighbour overlaps of the modules and compared with the average value of our neighbour overlaps (for the NOA hubs across all cancer types).

Validation using the METABRIC cohort

Normalised gene expression data and segmented copy number profiles for two METABRIC breast cancer cohorts ($N_{\text{discovery}} = 997$ and $N_{\text{validation}} = 995$) (EGAS000000000083) were downloaded from the European Genome-phenome Archive (https://www.ebi.ac.uk/ega/). After removing cases with NAs, the validation set was reduced to 987 samples.

We adjusted the gene expression data for age and breast cancer subtypes (PAM50) using svaseq. We repeated our analysis pipeline for 336 high-stress phenotype samples and 319 low-stress phenotype samples for the discovery set and 300 and 375 for the validation set, respectively.

Validation using Project Achilles

The Achilles CRISPR data set (Avana-17Q2-Broad_v2) was downloaded from the Broad Institute data set portal (https://portals.broadinstitute.org/achilles/).

This data set includes 341 cancer cell lines, for which the individual genes have been systemically perturbed using CRISPR-Cas9 to identify their effects on survival. Hundred and twenty-eight NOA rewiring hubs were present in the Achilles data set. We performed a permutation test, where the Achilles data set were subsampled 10,000 times with a sample size of 128 genes to assess the significance of the Achilles score for our NOA rewiring hubs. We also performed a Wilcoxon rank sum test to test if the NOA Achilles score distribution differed from the average Achilles score distribution.

Additional resources

The protein interaction data set, InWeb.IM, is available at http://www.lagelab.org/resources/. TCGA CNA and RNA-Seq profiles are available at https://cancergenome.nih.gov/. TCGA raw read count RNA-Seq data are available at https://www.ncbi.nlm.nih.gov/geo/. TCGA RNAseq-CNA correlation tables are available at http://firebrowse.org/. The Project Achilles data set is available at https://portals.broadinstitute.org/achilles. The METABRIC datasets can be applied for through https://www.ebi.ac.uk/ega/.

Reporting summary

Further information on research design is available in the Nature Research Reporting Summary linked to this article.

DATA AVAILABILITY

Copy number variation data were downloaded from The Cancer Genome Atlas (TCGA) (https://cancergenome.nih.gov/) and TCGA RNA-seq data (raw read counts) were obtained from the GEO (Gene Expression Omnibus) (https://www.ncbi.nlm.nih.gov/geo/) data set GSE6294455.

ACKNOWLEDGEMENTS

We would like to acknowledge the Novo Nordisk Foundation (grant agreement NNF14CC0001), the Innovation Fund Denmark (grant agreement 5153-0002B) as well as the NIH grant (grant agreement U54-CA192905) for funding the research. F.R. and D.W. were supported by the BRIDGE – Translational Excellence Programme (bridge.ku.dk), Faculty of Health and Medical Sciences, University of Copenhagen, funded by the Novo Nordisk Foundation (Grant agreement no. NNF16SA0034956). We would like to acknowledge the TCGA research consortium to provide an open access resource for our study and the METABRIC consortium for the validation data. Finally, we would like to thank the researchers in Brunak Lab for useful discussions and suggestions.

AUTHOR CONTRIBUTIONS

J.X.H designed the study, directed the systems biology analysis, prepared the illustrations and wrote the paper. J.X.H and F.R. conducted the data analysis. L.J.J. and D.W. aided the systems biology analysis. S.B. and J.M.I. helped to direct the study. All authors read and approved the final paper.

ADDITIONAL INFORMATION

Supplementary Information accompanies the paper on the npj Systems Biology and Applications website (https://doi.org/10.1038/s41540-019-0104-5).

Competing interests: The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

REFERENCES

1. Solimini, N. L., Luo, J. & Elledge, S. J. Non-oncogene addiction and the stress phenotype of cancer cells. Cell 130, 986–988 (2007).
2. Nagel, R. et al. Drugging the addict: non-oncogene addiction as a target for cancer therapy. EMBO Rep. 17, 1516–1531 (2016).
3. Califano, A. & Alvarez, M. J. The recurrent architecture of tumour initiation, progression and drug sensitivity. Nat. Rev. Cancer 17, 116–130 (2016).
4. Luo, J., Solimini, N. L. & Elledge, S. J. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136, 823–837 (2009).
5. Costanzo, M. et al. A global genetic interaction network maps a wiring diagram of cellular function. Science 353, aaf1420–aaf1420 (2016).
6. O’Neil, N. J., Bailey, M. L. & Hieter, P. Synthetic lethality and cancer. Nat. Rev. Genet. 18, 613–623 (2017).
9. Curtis, C. et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups.
10. Jia, L., Li, B. & Yu, H. The Bub1 Plk1 kinase complex promotes spindle checkpoint signalling through Cdc20 phosphorylation.
11. Hsu, C., Juan, H.-F. & Huang, H.-C. Functional analysis and characterization of differential coexpression networks. Sci. Rep. 5, 13295 (2015).
12. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation.
13. Hieronymus, H. et al. Copy number alteration burden predicts prostate cancer relapse. Proc. Natl Acad. Sci. USA 111, 11139–11144 (2014).
14. Langfelder, P. & Horvath, S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 9, 559 (2008).
15. Teison, B. M., Brentling, R. & Jansen, R. C. DiffCoEx: a simple and sensitive method to find differentially coexpressed gene modules. BMC Bioinformatics. 11, 497 (2010).
16. Ideker, T. & Krogan, N. J. Differential network biology. Mol. Syst. Biol. 8, 1–9 (2012).
17. Chalmers, Z. R. et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 9, 1–14 (2017).
18. Hein, M. Y. et al. A human interactome in three quantitative dimensions organized by stoichiometries and abundances. Cell 163, 712–723 (2015).
19. Li, T. et al. A scored human protein-protein interaction network to catalyze genomic interpretation. Nat. Methods 064535, https://doi.org/10.1038/nmeth.4083 (2016).
20. Dietel, F., Thelen, L. & Reinhardt, H. C. Cancer-specific defects in DNA repair pathways as targets for personalized therapeutic approaches. Trends Genet. 30, 326–339 (2014).
21. Barabási, A.-L. & Oltvai, Z. N. Network biology: understanding the cell’s functional organization. Nat. Rev. Genet. 5, 101–113 (2004).
22. Hu, J. X., Thomas, C. E. & Brunak, S. Network biology concepts in complex disease comorbidities. Nat. Rev. Genet. 17, 615–629 (2016).
23. Reimand, J. et al. gProfiler—a web server for functional interpretation of gene lists (2016 update). Nucleic Acids Res. 1–7, https://doi.org/10.1093/nar/gkw19 (2016).
24. Pasquale, E. B. Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat. Rev. Cancer 10, 165–180 (2010).
25. Wang, J. et al. Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK. Nat. Commun. 7, 11363 (2016).
26. van Vught, M. A. T. M. & Medema, R. H. Getting in and out of mitosis with Polo-like kinase-1. Oncogene 24, 2844–2859 (2005).
27. Lee, E. et al. Sensitivity to BUB1B inhibition defines an alternative classification of glioblastoma. Cancer Res. 064535, https://doi.org/10.1158/0008-5472. CAN-17-0736 (2017).
28. Ding, Y. et al. Cancer-specific requirement for BUB1/BUBR1 in human brain tumor isolates and genetically transformed cells. Cancer Discov. 3, 198–211 (2013).
29. Candelario, K. M. & Steindler, D. A. The role of extracellular vesicles in the progression of neurodegenerative disease and cancer. Trends Mol. Med. 20, 368–374 (2014).
30. Jia, L., Li, B. & Yu, H. The Bub1–Plk1 kinase complex promotes spindle checkpoint signalling through Cdc20 phosphorylation. Nat. Commun. 7, 10818 (2016).
31. Baker, D. J. et al. Increased expression of BubR1 protects against aneuploidy and cancer in fragile X syndrome mouse models. Nat. Cell Biol. 15, 96–102 (2012).
32. Uhlen, M. et al. A pathology atlas of the human cancer transcriptome. Science 357, PMID27597964 (2017).
33. Curtis, C. et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486, 346–352 (2012).
34. Tsherniak, A. et al. Defining a cancer dependency map. Cell 170, 564–570 (2017).
35. Califano, A. Rewiring makes the difference. Mol. Syst. Biol. 7, 463 (2011).
36. Bryant, H. E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913–917 (2005).
37. Olivo, M. et al. The stress phenotype makes cancer cells addicted to CD2T, a substrate inhibitor of the CRL4 ubiquitin ligase. Oncotarget 5, 5992–6002 (2014).
38. Dai, C., Whitesell, L., Rogers, A. B. & Lindquist, S. Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis. Cell 130, 1005–1018 (2007).
39. Gordon, D. J., Resio, B. & Pellman, D. Causes and consequences of aneuploidy in cancer. Nat. Rev. Genet. 13, 189–203 (2012).
40. Calderwood, S. K., Khaled, M. A., Sawyer, D. B. & Ciocca, D. R. Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem. Sci. 31, 164–172 (2006).
41. Collins, F. S., Lander, E. S., Rogers, J. & Waterson, R. H. Finishing the euchromatic sequence of the human genome. Nature. https://doi.org/10.1038/nature03001 (2004).
42. Chen, P. H. et al. Crosstalk between CLCβ/Dyn1-mediated adaptive clathrin-mediated endocytosis and epidermal growth factor receptor signaling increases metastasis. Dev. Cell 40, 278–288.e5 (2017).
43. McDonald, E. R. et al. Project DRIVE: a compendium of cancer dependencies and synthetic lethal relationships uncovered by large-scale, deep RNAi screening. Cancer 170, 577–592.e10 (2017).
44. Krogan, N. J., Lippman, S., Agard, D. A., Ashworth, A. & Ideker, T. The cancer cell map initiative: defining the hallmark networks of cancer. Mol. Cell 58, 690–698 (2015).
45. Ryan, C. J., Lord, C. J. & Ashworth, A. DAISY: picking synthetic lethals from cancer genomes. Cancer Cell 26, 306–308 (2014).
46. Adamsson, B. et al. A multiplexed single-cell CRISP2 screening platform enables systematic dissection of the unfolded protein response. Cell 167, 1867–1882.e21 (2016).
47. Shalek, A. K. & Benson, M. Single-cell analyses to tailor treatments. Sci. Transl. Med. 9, eaan4730 (2017).
48. Goldenberg, B. & Crispino, J. D. The aurora kinases in cell cycle and leukemia. Oncogene 34, 537–545 (2015).
49. Carpinelli, P. & Moll, J. Aurora kinases and their inhibitors: more than one target and one drug. Adv. Exp. Med. Biol. 610, 54–73 (2008).
50. Gjertsen, B. T. & Schöffski, P. Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy. Leukemia 11–19, https://doi.org/10.1038/leu.2014.222 (2014).
51. Strebhardt, K. & Ullrich, A. Targeting polo-like kinase 1 for cancer therapy. Nat. Rev. Cancer 6, 321–330 (2006).
52. Ma, C. X., Janetka, J. W. & Piwnica-Worms, H. Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics. Trends Mol. Med. 17, 88–96 (2011).
53. Sherman, M. Y. & Gabai, V. L. Hsp70 in cancer: back to the future. Oncogene 34, 1–9 (2014).
54. Damodaran, A. P., Vaufrey, L., Gavard, O., Frigent, C. & Aurora, A. Kinase is a priority pharmaceutical target for the treatment of cancers.Trends Pharmacol. Sci. Trends Pharmacol. Sci. https://doi.org/10.1016/j.tips.2017.05.003 (2017).
55. Rahman, M. et al. Alternative preprocessing of RNA-Sequencing data in the Cancer Genome Atlas leads to improved analysis results. Bioinformatics 31, 3666–3672 (2015).
56. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
57. Lin, S. M., Du, P., Huber, W. & Ribbe, W. A. Model-based variance-stabilization transformation for Illumina microarray data. Nucleic Acids Res. 36, PMID18178591 (2008).
58. Leek, J. T., Johnson, W. E., Parker, H. S., Jaffe, A. E. & Storey, J. D. The SVA package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics 28, 882–883 (2012).
59. Laddha, S. V., Ganesan, S., Chan, C. S. & White, E. Mutational landscape of the essential autophagy gene BECN1 in human cancers. Mol. Cancer Res. 12, 485–490 (2014).
60. Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: A Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139–140 (2010).